4//SEC Filing
Hambleton Julie 4
Accession 0001104659-25-012362
CIK 0001773427other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 7:57 PM ET
Size
9.1 KB
Accession
0001104659-25-012362
Insider Transaction Report
Form 4
Hambleton Julie
Director
Transactions
- Exercise/Conversion
Common Stock
2025-02-10$32.27/sh+13,774$444,487→ 17,869 total - Sale
Common Stock
2025-02-10$53.01/sh−13,774$730,207→ 4,095 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-10−13,774→ 0 totalExercise: $32.27Exp: 2033-05-24→ Common Stock (13,774 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The shares underlying this option are fully vested.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
Related Parties
1- filerCIK 0001578771
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 7:57 PM ET
- Size
- 9.1 KB